FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254831001> ?p ?o ?g. }

• W4254831001 endingPage "2850" @default.
• W4254831001 startingPage "2850" @default.
• W4254831001 abstract "Abstract Abstract 2850 Introduction: Based on recent favorable in vitro and in vivo activity of several HDACi (histone deacetylase inhibitors) in HL (Hodgkin lymphoma), we investigated the in vitro activity of SNDX-275, an oral, class 1 isoform of selective HDACi in HL-derived cell lines. Materials and methods: Proliferation and cell death were examined by MTS assay, Annexin-V/PI and FACS analysis. For combination studies, cells were incubated with SNDX-275 (0.1-2 μM) and either ABT-737 (0.01-0.2 μM), Obatoclax (0.1-2 μM), Gemcitabine (1-20 nM) or Bortezomib (1-20 nM) for 72 hours. Gene and protein expression were measured by RT-PCR, Western blot, and immunohistochemistry. A multiplex assay was used to determine 30 cytokines and chemokines. Results: SNDX-275 induced cell death in a dose and time dependent manner with an IC50 of 0.4 μM. At the molecular level, SNDX-275 increased histone-3 acetylation, up-regulated p21 expression, and activated the intrinsic apoptosis pathway by down-regulating the XIAP (X-linked inhibitor of apoptosis protein), which was associated with activation of Caspase 9 and 3. Similarly to other HDACis, SNDX-275 decreased the expression of anti-apoptotic Bcl-2 and Bcl-xL, while level of Mcl-1 and pro-apoptotic Bax remained the same level. Combination studies demonstrated that SNDX-275 had more synergistic effect when combined with Bcl-2 inhibitors ABT-737 or Obatoclax and less when combined with Gemcitabine or Bortezomib. Dysregulated cytokine/chemokine production has been shown previously to contribute to HL pathology, including immune tolerance of the cancer cells. Hence, we measured the effect of SNDX-275 on pathways that may contribute to an anti-tumor immune response. Increased IL12 p40-70, IP10, and RANTES, and decreased IL13, IL4 and TARC levels were found, thus favoring Th1-type cytokines/chemokines. Recent data has demonstrated that a variety of epigenetic-modulating drugs may up-regulate the expression of CTAs (cancer testis antigens), leading to a favorable immune response. SNDX-275 was able to induce CTA expression of SSX2 and NY-ESO only in one cell line whereas MAGE-A4 was induced in both HL cell lines. Conclusion: Our studies demonstrate that SNDX-275 has a dual effect on apoptotic and immunomodulatory pathways in HL, which can be enhanced by the addition of agents targeting cell survival pathways. Phase II studies with SNDX-275 in HL are ongoing, future clinical studies should investigate combinations with SNDX-275. Disclosures: No relevant conflicts of interest to declare." @default.
• W4254831001 created "2022-05-12" @default.
• W4254831001 creator A5002306207 @default.
• W4254831001 creator A5002316929 @default.
• W4254831001 creator A5006134549 @default.
• W4254831001 creator A5012342629 @default.
• W4254831001 creator A5041105618 @default.
• W4254831001 creator A5041376760 @default.
• W4254831001 creator A5048978229 @default.
• W4254831001 creator A5068152076 @default.
• W4254831001 creator A5087013892 @default.
• W4254831001 date "2010-11-19" @default.
• W4254831001 modified "2023-10-16" @default.
• W4254831001 title "The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction" @default.
• W4254831001 doi "https://doi.org/10.1182/blood.v116.21.2850.2850" @default.
• W4254831001 hasPublicationYear "2010" @default.
• W4254831001 type Work @default.
• W4254831001 citedByCount "2" @default.
• W4254831001 countsByYear W42548310012023 @default.
• W4254831001 crossrefType "journal-article" @default.
• W4254831001 hasAuthorship W4254831001A5002306207 @default.
• W4254831001 hasAuthorship W4254831001A5002316929 @default.
• W4254831001 hasAuthorship W4254831001A5006134549 @default.
• W4254831001 hasAuthorship W4254831001A5012342629 @default.
• W4254831001 hasAuthorship W4254831001A5041105618 @default.
• W4254831001 hasAuthorship W4254831001A5041376760 @default.
• W4254831001 hasAuthorship W4254831001A5048978229 @default.
• W4254831001 hasAuthorship W4254831001A5068152076 @default.
• W4254831001 hasAuthorship W4254831001A5087013892 @default.
• W4254831001 hasConcept C104317684 @default.
• W4254831001 hasConcept C153911025 @default.
• W4254831001 hasConcept C185592680 @default.
• W4254831001 hasConcept C190283241 @default.
• W4254831001 hasConcept C203014093 @default.
• W4254831001 hasConcept C2776202225 @default.
• W4254831001 hasConcept C2776364478 @default.
• W4254831001 hasConcept C2777478702 @default.
• W4254831001 hasConcept C2778305200 @default.
• W4254831001 hasConcept C2781462825 @default.
• W4254831001 hasConcept C31573885 @default.
• W4254831001 hasConcept C33195913 @default.
• W4254831001 hasConcept C502942594 @default.
• W4254831001 hasConcept C55493867 @default.
• W4254831001 hasConcept C64927066 @default.
• W4254831001 hasConcept C86803240 @default.
• W4254831001 hasConcept C98424977 @default.
• W4254831001 hasConceptScore W4254831001C104317684 @default.
• W4254831001 hasConceptScore W4254831001C153911025 @default.
• W4254831001 hasConceptScore W4254831001C185592680 @default.
• W4254831001 hasConceptScore W4254831001C190283241 @default.
• W4254831001 hasConceptScore W4254831001C203014093 @default.
• W4254831001 hasConceptScore W4254831001C2776202225 @default.
• W4254831001 hasConceptScore W4254831001C2776364478 @default.
• W4254831001 hasConceptScore W4254831001C2777478702 @default.
• W4254831001 hasConceptScore W4254831001C2778305200 @default.
• W4254831001 hasConceptScore W4254831001C2781462825 @default.
• W4254831001 hasConceptScore W4254831001C31573885 @default.
• W4254831001 hasConceptScore W4254831001C33195913 @default.
• W4254831001 hasConceptScore W4254831001C502942594 @default.
• W4254831001 hasConceptScore W4254831001C55493867 @default.
• W4254831001 hasConceptScore W4254831001C64927066 @default.
• W4254831001 hasConceptScore W4254831001C86803240 @default.
• W4254831001 hasConceptScore W4254831001C98424977 @default.
• W4254831001 hasIssue "21" @default.
• W4254831001 hasLocation W42548310011 @default.
• W4254831001 hasOpenAccess W4254831001 @default.
• W4254831001 hasPrimaryLocation W42548310011 @default.
• W4254831001 hasRelatedWork W1521194800 @default.
• W4254831001 hasRelatedWork W1995443667 @default.
• W4254831001 hasRelatedWork W2021565270 @default.
• W4254831001 hasRelatedWork W2042644227 @default.
• W4254831001 hasRelatedWork W2092526933 @default.
• W4254831001 hasRelatedWork W2491125089 @default.
• W4254831001 hasRelatedWork W2558950888 @default.
• W4254831001 hasRelatedWork W2980387245 @default.
• W4254831001 hasRelatedWork W4254831001 @default.
• W4254831001 hasRelatedWork W4361949278 @default.
• W4254831001 hasVolume "116" @default.
• W4254831001 isParatext "false" @default.
• W4254831001 isRetracted "false" @default.
• W4254831001 workType "article" @default.